medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2018, Número 6

<< Anterior Siguiente >>

Ann Hepatol 2018; 17 (6)


MicroRNA Profile in Peripheral Blood Mononuclear Cells from Hepatitis B Virus Infected Patients

Yu K, Li Q, Li N

Idioma: Español
Referencias bibliográficas: 32
Paginas: 1012-1020
Archivo PDF: 1339.95 Kb.


RESUMEN

Sin resumen.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. 1.European Association for the Study of the L. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol 2017; 67: 370-98.

  2. 2.Serigado JM, Izzy M, Kalia H. Novel therapies and potential therapeutic targets in the management of chronic hepatitis B. Eur J Gastroenterol Hepatol 2017; 29: 987-93.

  3. 3.Selbach M, Schwanhausser B, Thierfelder N, Fang Z, Khanin R, Rajewsky N. Widespread changes in protein synthesis induced by microRNAs. Nature 2008; 455: 58-63.

  4. 4.Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell 2009; 136: 215-33.

  5. 5.Ambros V. The functions of animal microRNAs. Nature 2004; 431: 3505.

  6. 6.Murakami Y, Yasuda T, Saigo K, Urashima T, Toyoda H, Okanoue T, Shimotohno K. Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues. Oncogene 2006; 25: 2537-45.

  7. 7.Kloosterman WP, Plasterk RH. The diverse functions of microRNAs in animal development and disease. Dev Cell 2006; 11: 441-50.

  8. 8.Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, et al. MicroRNA expression profiles classify human cancers. Nature 2005; 435: 834-8.

  9. 9.Zhou J, Yu L, Gao X, Hu J, Wang J, Dai Z, Wang JF, et al. Plasma microRNA panel to diagnose hepatitis B virus-related hepatocellular carcinoma. J Clin Oncol 2011; 29: 4781-8.

  10. 10.Borel F, Konstantinova P, Jansen PL. Diagnostic and therapeutic potential of miRNA signatures in patients with hepatocellular carcinoma. J Hepatol 2012; 56: 1371-83.

  11. 11.Yan X, Zhu Z, Xu S, Yang LN, Liao XH, Zheng M, Yang D, et al. MicroRNA-140-5p inhibits hepatocellular carcinoma by directly targeting the unique isomerase Pin1 to block multiple cancer-driving pathways. Sci Rep 2017; 7: 45915.

  12. 12.Ji F, Yang B, Peng X, Ding H, You H, Tien P. Circulating microRNAs in hepatitis B virus-infected patients. J Viral Hepat 2011; 18: e242-51.

  13. 13.Tang Y, Luo X, Cui H, Ni X, Yuan M, Guo Y, Huang X, et al. MicroRNA-146A contributes to abnormal activation of the type I interferon pathway in human lupus by targeting the key signaling proteins. Arthritis Rheum 2009; 60: 1065-75.

  14. 14.Li N, Li Q, Qian Z, Zhang Y, Chen M, Shi G. Impaired TLR3/ IFN-beta signaling in monocyte-derived dendritic cells from patients with acute-on-chronic hepatitis B liver failure: relevance to the severity of liver damage. Biochem Biophys Res Commun 2009; 390: 630-5.

  15. 15.Bindea G, Mlecnik B, Hackl H, Charoentong P, Tosolini M, Kirilovsky A, Fridman WH, et al. ClueGO: a Cytoscape plug-in to decipher functionally grouped gene ontology and pathway annotation networks. Bioinformatics 2009; 25: 1091-3.

  16. 16.Panteva M, Korkaya H, Jameel S. Hepatitis viruses and the MAPK pathway: is this a survival strategy? Virus Res 2003; 92: 131-40.

  17. 17.Chin R, Earnest-Silveira L, Koeberlein B, Franz S, Zentgraf H, Dong X, Gowans E, et al. Modulation of MAPK pathways and cell cycle by replicating hepatitis B virus: factors contributing to hepatocarcinogenesis. J Hepatol 2007; 47: 325-37.

  18. 18.Han M, Yan W, Guo W, Xi D, Zhou Y, Li W, Gao S, et al. Hepatitis B virus-induced hFGL2 transcription is dependent on c- Ets-2 and MAPK signal pathway. J Biol Chem 2008; 283: 32715-29.

  19. 19.Wang S, Chen Z, Hu C, Qian F, Cheng Y, Wu M, Shi B, et al. Hepatitis B virus surface antigen selectively inhibits TLR2 ligand-induced IL-12 production in monocytes/macrophages by interfering with JNK activation. J Immunol 2013; 190: 5142-51.

  20. 20.Huang HC, Chen CC, Chang WC, Tao MH, Huang C. Entry of hepatitis B virus into immortalized human primary hepatocytes by clathrin-dependent endocytosis. J Virol 2012; 86: 9443-53.

  21. 21.Thompson MD, Monga SP. WNT/beta-catenin signaling in liver health and disease. Hepatology 2007; 45: 1298-305.

  22. 22.Edamoto Y, Hara A, Biernat W, Terracciano L, Cathomas G, Riehle HM, Matsuda M, et al. Alterations of RB1, p53 and Wnt pathways in hepatocellular carcinomas associated with hepatitis C, hepatitis B and alcoholic liver cirrhosis. Int J Cancer 2003; 106: 334-41.

  23. 23.Han MS, Barrett T, Brehm MA, Davis RJ. Inflammation Mediated by JNK in Myeloid Cells Promotes the Development of Hepatitis and Hepatocellular Carcinoma. Cell Rep 2016; 15: 19-26.

  24. 24.Yuan F, Zhou W, Zou C, Zhang Z, Hu H, Dai Z, Zhang Y. Expression of Oct4 in HCC and modulation to wnt/beta-catenin and TGF-beta signal pathways. Mol Cell Biochem 2010; 343: 155-62.

  25. 25.Xia L, Tian D, Huang W, Zhu H, Wang J, Zhang Y, Hu H, et al. Upregulation of IL-23 expression in patients with chronic hepatitis B is mediated by the HBx/ERK/NF-kappaB pathway. J Immunol 2012; 188: 753-64.

  26. 26.Yu K, Li Q, Cheng Q, Huang C, Zheng J, Chen S, Ling Q, et al. MicroRNA-548j inhibits type I interferon production by targeting ZBTB11 in patients with chronic hepatitis B. Biochem Biophys Res Commun 2017; 488: 628-33.

  27. 27.Gottlob K, Fulco M, Levrero M, Graessmann A. The hepatitis B virus HBx protein inhibits caspase 3 activity. J Biol Chem 1998; 273: 33347-53.

  28. 28.Kekule AS, Lauer U, Weiss L, Luber B, Hofschneider PH. Hepatitis B virus transactivator HBx uses a tumour promoter signalling pathway. Nature 1993; 361: 742-5.

  29. 29.Zhou J, Ju WQ, Yuan XP, Zhu XF, Wang DP, He XS. miR-26a regulates mouse hepatocyte proliferation via directly targeting the 3’ untranslated region of CCND2 and CCNE2. Hepatobiliary Pancreat Dis Int 2016; 15: 65-72.

  30. 30.Thuerauf DJ, Morrison L, Glembotski CC. Opposing roles for ATF6alpha and ATF6beta in endoplasmic reticulum stress response gene induction. J Biol Chem 2004; 279: 21078-84.

  31. 31.Thuerauf DJ, Marcinko M, Belmont PJ, Glembotski CC. Effects of the isoform-specific characteristics of ATF6 alpha and ATF6 beta on endoplasmic reticulum stress response gene expression and cell viability. J Biol Chem 2007; 282: 22865-78.

  32. Yamamoto M, Ma JS, Mueller C, Kamiyama N, Saiga H, Kubo E, Kimura T, et al. ATF6beta is a host cellular target of the Toxoplasma gondii virulence factor ROP18. J Exp Med 2011; 208: 1533-46.




2020     |     www.medigraphic.com